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ABSTRACT
Background and Aims: A growing body of evidence supports the need for
detailed attention to nutrition and diet in children with inflammatory bowel
disease (IBD). We aimed to define the steps in instituting dietary or
nutritional management in light of the current evidence and to offer a useful
and practical guide to physicians and dieticians involved in the care of
pediatric IBD patients.
Methods: A group of 20 experts in pediatric IBD participated in an
iterative consensus process including 2 face-to-face meetings,
following an open call to Nutrition Committee of the European
Society of Pediatric Gastroenterology, Hepatology and Nutrition
Porto, IBD Interest, and Nutrition Committee. A list of 41
predefined questions was addressed by working subgroups based on
a systematic review of the literature.
Results: A total of 53 formal recommendations and 47 practice points were
endorsed with a consensus rate of at least 80% on the following topics:
nutritional assessment; macronutrients needs; trace elements, minerals, and
vitamins; nutrition as a primary therapy of pediatric IBD; probiotics and
prebiotics; specific dietary restrictions; and dietary compounds and the risk
of IBD.
Conclusions: This position paper represents a useful guide to help the
clinicians in the management of nutrition issues in children with IBD.
Key Words: Crohn disease, enteral nutrition, inflammatory bowel disease,
nutrition, nutritional therapy, pediatrics, ulcerative colitis
(JPGN 2018;66: 687–708)
What Is Known
 A growing body of evidence supports the need for
detailed attention to nutrition and diet in children
with inflammatory bowel disease.
 Despite the increasingly recognized importance of
the issue, no specific pediatric dietary guidelines
have been published to date.
What Is New
 We provide clear recommendations to better
define the steps in instituting nutritional manage-
ment in light of the current evidence.
 This position paper represents a useful practical
guide to help physicians and dieticians involved in
the care of pediatric inflammatory bowel disease
patients.
I nflammatory bowel diseases (IBD), including Crohn disease(CD), ulcerative colitis (UC), and IBD-unclassified (IBD-U), are
chronic and relapsing intestinal disorders, causing abdominal pain,
diarrhea, rectal bleeding, and weight loss. Therefore, it is not
surprising that parents and children with IBD believe that diet is
relevant to their child’s condition and that they try to modify their
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diet accordingly. In particular, children with IBD often tend to avoid
foods more than they would specifically need to. Thus, a growing
body of evidence supports the need for detailed attention to nutrition
and diet in children with IBD. Indeed, the relationship between
nutrition and IBD encompasses several areas including nutritional
support for malnourished patients, the use of exclusive enteral
nutrition (EEN) as primary therapy for treatment of CD, and the
role of specific nutrients as a risk factor for disease development (1).
There is wide variation in the dietary behaviors of children and the
strength of recommendations for them, although most physicians do
not routinely endorse specific diets for patients with IBD (2).
Dietary factors may have beneficial or deleterious effects. Simple
advice regarding avoidance of some foods without balancing the
diet with recommended alternatives may inadvertently reduce the
overall amount of calories, macronutrients, and micronutrients
provided, contributing to the malnutrition and specific nutritional
deficiencies in pediatric IBD patients (3,4).
Recently, on the basis of the increasing knowledge regarding
the efficacy of EEN for the induction of remission of pediatric CD,
several attempts have been made to define new therapeutic avenues
for the dietary treatment of pediatric IBD. Nevertheless, to date, in
addition to the use of EEN, most ‘‘best-evidence’’ guidelines offer
no recommendations for the use of specific diet in the therapy of
IBD (5).
Thus, the purposes of this position paper are to define the
steps in instituting dietary or nutritional management in light of the
current evidence and to offer a useful and practical guide to
physicians and dieticians involved in the care of pediatric
IBD patients.
METHODS
Apanel of experts was selected inApril 2016 after an open call
among the Pediatric IBD Porto Group, the IBD Interest Group, and
the Nutrition Committee of the European Society of Pediatric
Gastroenterology, Hepatology and Nutrition (ESPGHAN). The first
face-to-face meeting resulted in organizing the position paper into 7
different sections, namely, nutritional assessment; macronutrients
needs; trace elements, minerals and vitamins; nutrition as a primary
therapy of pediatric IBD; probiotics and prebiotics; specific dietary
restrictions; and, dietary compounds and the risk of IBD.Within these
7 sections a total of 10 topics were then assigned to 10 different
working subgroups. Each working subgroup was asked to define the
most relevant questions within their specific topic and to perform a
literature search using Medline-PubMed and the Cochrane Library
databases with appropriate search strategies (available upon request)
using a last search date ofMay 1, 2016. Subgroupswere also asked to
grade the levels and the quality of evidence using the classification
system of the Oxford Centre for Evidence-Based Medicine (http://
www.cebm.net/mod_product/design/files/CEBM-Levels-ofEvidence-
2.1.pdf). Questions were answered using the results of systematic
literature searches and the resultant expert opinions. A total of 2 face-
to-face meetings were held in Athens and Vienna to achieve consen-
sus on formulate and agree on all of the recommendations. All group
members interacted during these 2 face-to-facemeetings, by iterative
e-mails in the formof amodifiedDelphi process and byan e-platform.
All recommendations were voted on and accepted when at least 80%
agreement was achieved.
NUTRITIONAL ASSESSMENT
Dietary History
Is there a need for regular dietary assessment in children with
IBD?
Statement:
 The assessment of dietary intake should be an
integral part of the follow-up of pediatric IBD
patients (Evidence Level [EL] 3).
Patients with IBD can tend to self-impose elimination diets to
control the symptoms such as diarrhea and abdominal pain (6). The
most commonly excluded foods are grains (29%), milk (28%),
vegetables (18%), and fruits (11%) (6). Studies on dietary quality
and nutritional intake of IBD patients have used different assess-
ment tools and only 2 studies specifically address issues in children
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(7,8). The diet of IBD patients differed significantly from that
of healthy controls and/or recommended daily allowance
(RDA). Most commonly, intake was significantly lower for
energy, fibers, and carbohydrates and for several vitamins
(mostly fat soluble and vitamin C) and minerals (Ca, P, Mg,
Fe). In children, both studies showed significantly decreased
intake of energy, Ca, and Fe (7,8). Poor dietary intake is
consistent in both active disease and in remission additionally
in both UC and CD (7).
Which method of dietary assessment is preferable and how
often should it be performed?
Statement:
 A 3- to 5-day dietary record (DR) is recommended
for the assessment of dietary intake (EL 4).
Practice points:
 No current method can give a complete snapshot
of dietary intake over time.
 In the follow-up of patients with IBD, the ideal is to
repeat the 3- to 5-day DR (in quality and quantity)
twice a year in younger children, and once a year in
adolescents, when found appropriate by the treat-
ing physician and/or dietician.
Methods used to assess dietary intake of IBD patients
differ, and none suit all purposes (9). The food frequency
questionnaire was standardized and validated, and performs well
to investigate the relationship between a certain type of diet or
dietary component and the risk for disease (10). The 3-to 5-day
DR is better equipped for quantitative evaluation of energy and
nutrient intake. Several studies have compared the performance
of food frequency questionnaire and DR with differing results
(11,12). Recently published guidelines on nutritional care for
children with cystic fibrosis recommend to use the 3- to 5-day
DR every 3 months in children and every 6 months in adult
patients (13). Because nutritional risks are less severe in children
with IBD, it seems reasonable to assess dietary intake at least
twice per year in small children (5 years) and once per year
(every 12 months) in older children and adolescents or addition-
ally whenever deemed necessary by the physician and/
or dietician.
Anthropometry, Body Composition, Puberty
What is the importance and etiology of
undernutrition?
Statement:
 Malnutrition and impaired linear growth can be
markers of disease activity; their restoration should
be considered as a treatment goal (EL 2).
Linear growth impairment can precede any other symp-
tom by many years in up to 46% of pediatric patients with CD
(14–16). In the 80s and the 90s the prevalence of growth
retardation and malnutrition were around 24% to 46%
(15,17–19), More recent studies such as population cohorts
(20),and multicenter registries (21,22) report significantly
decreased body mass index (BMI) at diagnosis in 17% to
32%, and poor growth in 8% to 10%. Furthermore, impaired
linear growth persists in a significant proportion of patients
with CD irrespective of the treatment modality, and results in
decreased final adult height in 11% to 35% of patients with the
mean difference reaching 7 cm less than genetic height potential
(22–25). In UC patients, malnutrition and stunted growth affect
a lower proportion of patients (5%–12%) at diagnosis and do
not usually persist at follow-up (24).
In the pathogenesis of growth retardation, chronic undernu-
trition, inflammation (3,26–28), genetic background reflected in
parents’ heights (24), and recently discovered gene polymorphisms
(24,29–31) are all important contributors. Steroids may impair
growth by a direct effect on the growth plate contrasted with the
beneficial effect of resolving inflammation with short-term treat-
ment or low doses. Of note, not all studies found a significant
difference in growth and bone mineralization with respect to
treatment with steroids (19,21,26,32–35). For children with UC,
diarrhea with blood loss, abdominal pain, anorexia, and the effects
of drug therapy are the main contributors to the pathogenesis
of undernutrition.
Although it will be not thoroughly analyzed within this
paper, it has to be underlined that a variable percentage of children
with IBD ranging from 10% to 30% may present with obesity at
diagnosis (36,37). This percentage seems not to differ from the
general population and it is in line with the parallel obesity epidemic
(36). It is still unclear whether these patients may have poorer
disease outcomes, but it has been suggested that obese patients with
IBD may have suboptimal response to therapies (38). Therefore, a
weight loss should be envisaged as a possible adjunctive
therapeutic intervention.
Is body composition impaired in children with IBD?
Statement:
 Lean body mass is decreased in children with IBD,
particularly in CD. This deficit may persist after
clinical remission (EL 2).
Practice point:
 The impact of an intervention on body composi-
tion should be included as a treatment outcome in
clinical trials.
A recent systematic review examining body composition
in IBD included 22 studies of which 6 were prospective, 11
cross-sectional and others examined specific interventions (eg,
treatment, resection) (39). The general conclusions of the
systematic review are that children with IBD have reduced
lean body mass compared to control subjects. Most data origi-
nate from children with CD. After remission this deficit per-
sisted. Studies comparing children with CD to children with UC
found greater lean body mass deficits are present in children
with CD. The findings on body fat were inconsistent, varying
from decrease to augmentation and no change. There was no
evidence found that alterations in body composition were
related to gender or disease activity. One study, however,
reported persistent deficit in lean body mass in girls, even in
remission (40).
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Puberty
Is IBD-associated with delayed pubertal development?
Statement:
 IBD can be associated with delayed pubertal devel-
opment (EL 2).
Practice point:
 Pubertal stage should be assessed regularly from
diagnosis in children age 10 years and older, and at
least annually during follow-up visits until puberty
is completed.
It has long been known that IBD in children is associated
with pubertal delay (41). Despite improved treatment strategies,
pubertal development must be monitored closely because it still
leads to severe complications such as decreased mineral bone
density, short stature, and lack of self-esteem (42,43). Catch up
growth with treatment is better in early puberty (44). When asses-
sing body composition, the pubertal stage needs to be taken into
account. Genders differ in lean body mass accrual: girls before and
boys during puberty (39).
How and when to determine nutritional status and to measure
linear growth?
Statements:
 Weight, height, and BMI z scores should be used
for assessment of the nutritional status at each
clinic visit (EL 2).
 Longitudinal linear growth reflects disease course;
it should be assessed every 6 months by measuring
height velocity z scores or variations in height-for-
age standard deviation score (SDS) (EL 2).
Practice points:
 Anthropometric measures should be plotted into
the appropriate growth charts
 Height velocity depends on the pubertal status.
Therefore, both have to be determined concur-
rently.
Nutritional status is currently being expressed mainly as the
BMI SDS (z score) (20), but because BMI can be normal in stunted
children, the height and parental height should always be considered
too (13,24). To assess growth, a height percentile or height-for-age
SDS (z score) is appropriate for a single measurement. In children
with IBD longitudinal linear growth is, however, more important as it
reflects disease course and treatment success. In that respect, a change
in the height SDS and a height velocity SDS for a period of 6 to
12 months are the methods of choice. The height velocity SDS reflects
growth over a defined period (27), but it also depends on the patient’s
pubertal status. Therefore, in children with pubertal delay the change
in height SDS could be used as a reliable marker of the longitudinal
growth (26). In the recent European Crohn’s and Colitis Organization
(ECCO)/ESPGHAN consensus guidelines, the height velocity over a
period of 6 to 12 months expressed in SDS has been recommended as
the best measure to monitor growth in patients with CD, and if
unavailable, change of the height-for-age z score is appropriate (45).
MACRONUTRIENTS AND ENERGY NEEDS IN
INFLAMMATORY BOWEL DISEASE
Definition
Macronutrients are proteins, carbohydrates, and fat.
Are there increased energy and macronutrient requirements in
pediatric IBD?
Statement:
 There is insufficient evidence that pediatric IBD
patients have increased energy and macronutrient
requirements compared to healthy children (EL 4).
Practice point:
 In the case of insufficient intake dietary consulting is
recommended. The general intake may be
increased on an individual basis, by increasing food
intake and food fortification. If those are not enough
supplemental formula may be recommended or
increasing caloric density of supplements. When
needs cannot be met by oral feeds, adequate nutri-
tion can be provided by nasogastric feeds.
Several studies have investigated energy requirements in
children with inconsistent results. Evidence regarding Resting
Energy Expenditure (REE), which is the energy requirement for
an individual in resting condition that approximates basal metabolic
requirements, is conflicting. An increase in REE in patients with
active CD was demonstrated in several studies in adults (46–48) and
in children (49,50). Other studies, however, suggested that this is due
to changes in body composition rather than the hypermetabolism
found in adults (51,52) and in children (53). Data from adult studies
cannot be extrapolated to pediatrics because children have higher
energy requirements relative to their body size during growth.
Several studies compared predicted REE to measured REE; 6
studies found no significant difference (49,53–57). One study
reported that the predicting methods underestimated REE (58)
and another study (59) reported that the predicted REE overesti-
mated the measured REE.
When dealing with the question whether REE is affected by
disease activity, several studies reported no difference in REE
between patients with active or inactive disease (54,55,57,59),
whereas 1 study reported an increase in REE during active disease
(49). REE is influenced by body size and composition; therefore,
measurements of REE will differ and results depend on the method
by which this was adjusted to body size and composition.
Several studies measured changes in resting energy expen-
diture following therapy with anti-tumour necrosis factor alpha
(TNF) (infliximab) (55,60,61). No differences were found in REE
before and after anti-TNF therapy.
In summary, pediatric patients with IBD seem to have similar
requirements as healthy children. Nevertheless, subjects should be
monitored carefully for adequate and sufficient energy intake by
clinical dietitian. In order to measure REE in clinical practice, the
predicted equations are sufficient and indirect calorimetry may be
performed only in subjects who do not gain weight sufficiently
despite adequate nutrition and disease control.
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Is there increased protein requirement in pediatric
IBD?
Statement:
 Protein requirement for children with IBD in remis-
sion is similar to the requirement for healthy pop-
ulation. During active disease protein, however,
requirement may be increased (EL 4).
Practice point:
 During active disease with poor nutritional state,
weight loss or growth retardation, it may be
recommended to increase protein intake by at
least 25% initially, or until linear growth
has improved.
There are few studies that investigated this question in
children with IBD; several of them tested the effect of therapy
on protein metabolism. There is an increase in protein turnover
in children with IBD as reported by Thomas et al (62);
they demonstrated that this increase may be reduced after
induction of remission with corticosteroid therapy or an ele-
mental diet. In addition, whole body protein breakdown
increased significantly after 2 weeks of corticosteroid therapy
in children with newly diagnosed CD (63). Chronic inflamma-
tion or corticosteroid therapy, however, was not found to be
associated with alteration in protein metabolism as reported by
Motil et al (64).
Varille et al (49) presented a significant decrease in protein
breakdown after surgical resection of gut lesions in children with
mildly active CD. In addition, Steiner et al (63) reported a
significant reduction in proteolysis and protein synthesis in the
fasting and parenterally fed state following the initial infusion
of Infliximab.
We would recommend increasing protein intake during flares
above the recommendations for the healthy population for several
reasons: children are growing, during flares children often reduce
their food intake, and during inflammation there is protein loss.
During remission the protein requirements for patients with IBD
may, however, be as for the healthy population according to dietary
reference intake (DRI)/RDA recommendations.
Is there increased carbohydrate and fat requirement in pediat-
ric IBD?
There are no studies that demonstrate a difference in carbohy-
drates and fat requirements in pediatric patients with IBD compared
to healthy people. A minimum consumption of carbohydrate should
provide 45% to 60% of total energy consumption per day. In order to
meet fat requirements, different percentages of total daily energy
should be from fat based on different children’s ages (Table 1).
Is there a difference in fat type requirements in pediatric IBD?
Type of fat seems to influence IBD in animal models; diets
rich in fat and sugar cause alterations in the microbiome, affect the
integrity of the mucus layer and increase intestinal permeability
(65). Animal fat increased intestinal permeability in animal models
(66). There are, however, no human studies to investigate the
influence of consumption of different types of food on IBD patients
except for studies investigating supplementation with omega 3 for
induction and maintenance of remission in IBD patients. The data in
this field do not support routine use of omega 3 and therefore, the
recommendations for IBD patients are the same as for the healthy
population (67,68).
TRACE ELEMENTS, MINERALS, AND VITAMINS
Trace Elements (Zinc, Selenium)
What is the risk for deficiencies of trace elements in children
with IBD and should these be monitored?
Statement:
 Due to insufficient data, we do not recommend
routine measurement or supplementation of zinc
and selenium in children with IBD (EL 2).
Practice points:
 Clinically significant deficiency of zinc is uncom-
mon in children with IBD. It seems prudent to
assess zinc status during prolonged diarrheal epi-
sodes (>4 weeks).
 When zinc deficiency is encountered, a short
course (2–4 weeks) of oral zinc is usually sufficient
to restore adequate serum levels.
Zinc
Small cohorts of children with IBD yielded up to 40% zinc
deficiency, particularly in children with CD (69–71). Serum zinc
levels were shown to be significantly lower in pediatric CD patients
compared with healthy controls (72). Zinc consumption was
reported to be inadequate in up to 15% of children with IBD
(73). A daily oral supplement of 20 to 40 mg elemental zinc (for
2–3 weeks) was suggested for patients with significant diarrhea
(>300 g of stool/day) (74).
Selenium
Only a few studies reported significantly low mean selenium
levels, irrespective of disease activity and/or location, in both adult
UC and CD patients, compared with controls (75–79). Two small
pediatric cohort studies yielded contradictory results (72,80).
TABLE 1. Estimated energy requirements
Male and female
4–18 years
Percentage of total
calories per day RDA/AI
Protein 10%–30% Varies on the basis
of age and gender
Carbohydrate 45%–60% ND
Fat 40% 6–12 months;
35%–40% 1–3 years;
20%–25% >4 years
ND
Based on the following European Food Security authority (EFSA)
recommendations:
1. https://www.efsa.europa.eu/it/efsajournal/pub/2557.
2. https://www.efsa.europa.eu/it/efsajournal/pub/1462.
3. https://www.efsa.europa.eu/it/efsajournal/pub/1461.
AI ¼ adequate intake; RDA ¼ recommended daily allowance.
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Minerals (Iron, Magnesium, Calcium)
What is the most effective and safe treatment option of pediatric
IBD-associated iron deficiency anemia (IDA)?
What is the risk for deficiencies of other minerals in children
with IBD and should these be monitored?
Statements:
 Iron supplementation is recommended in all pedi-
atric IBD patients when IDA is present, to normal-
ize hemoglobin level and iron stores (EL 2).
 Oral iron supplementation is effective in IDA IBD
patients with mild (>10 g/dL) anemia and nega-
tive inflammatory markers (EL 4).
 Intravenous (IV) iron supplementation is the pre-
ferred method of supplementation for pediatric
patients with clinically active IBD (EL 4).
 Children with IBD should be monitored for recur-
rence of iron deficiency (ID) as this may indicate
persistent intestinal disease activity (EL 2).
 Due to insufficient data, we do not recommend
routine measurement or supplementation of mag-
nesium in children with IBD (EL 2).
 Measuring magnesium levels should be considered
in children with prolonged diarrhea (>4 weeks) and
those at risk of refeeding syndrome (EL 4).
 Calcium intake should be monitored in children
and adolescents with IBD and low calcium intake
should be supplemented (EL 2).
Practice points:
 Oral iron replacement is associated with high levels
of intolerance and consequent lack of adherence.
 IV ferric carboxymaltose supplementation is better
tolerated and superior to oral treatment, particu-
larly in active IBD with low hemoglobin<10 g/dL.
 When magnesium deficiency is encountered, a
short course (2–4 weeks) of oral magnesium is
usually sufficient to restore adequate serum levels.
 Due to insufficient evidence, we do not recom-
mend a specific dose for calcium supplementation,
but suggest following the European Food Safety
Authority (EFSA) recommendations for the general
pediatric population (ie, 450 mg calcium from age
1–3 years, 800 mg from age 4–8 years, 1150 mg
from age 9–18 years).
 Due to insufficient evidences the screening of bone
mass density trough dual-energy x-ray absorpti-
ometry (DXA) should not differ from the general
population and it should be only recommended in
those children at higher risk of osteoporosis.
Iron
ID, IDA, and anemia of chronic disease (ACD), recently
defined by ECCO guidelines are common in pediatric IBD (81–83).
Expectant management of IBD-associated anemia is associated
with persistence of the anemia, well beyond induction of remission,
in up to 50% of patients (84,85). The impact of ACD/IDA, which
may co-exist, and even ID on the quality of life (QoL) of IBD
patients, is considerable (83,86,87). Inflammatory cytokines affect
the hepcidin-ferroportin axis, which leads to reduced duodenal iron
absorption, while also reducing erythropoietin production contrib-
ute to the anemia in IBD patients (88–92). Due to the existence of
specific ECCO guidelines, this paper will not discuss in details all
markers of ID (83).
Oral iron can be delivered in various formulations (93). Oral
iron replacement is often associated with intolerance (nausea,
abdominal pain, and constipation) and consequent lack of adher-
ence (85,94,95). Oral iron therapy may enhance intestinal inflam-
mation and has been shown to alter the intestinal microbiome (96–
98). Recently, Rampton et al (99), have, however, shown that oral
iron supplementation did not increase disease activity during a 6-
week open study.
The first generation of IV iron products (high molecular
weight iron dextran) was associated with serious anaphylactic
reactions and should no longer be used (93,100,101). The second
generation of IV iron products (such as iron sucrose and ferric
carboxymaltose) appears to have better safety profiles (93–
95,102–106). In 2 retrospective reports of pediatric IBD patients
receiving either iron sucrose infusions (n¼ 75) or ferric carbox-
ymaltose (n¼ 72), there were only minor adverse reactions (20%
and 4%, respectively) with no serious adverse events (102,107).
Hemoglobin level significantly improved following 4 infusions of
iron sucrose. Although there are no studies in pediatric IBD
directly comparing oral versus IV iron supplementation, adult
IBD studies have shown the IV route to be better tolerated and
superior, particularly in active IBD with low hemoglobin<10 g/dL
(95,108).
Magnesium
Few studies demonstrated substantial rates of magnesium
deficiency in adult IBD patients (109,110) ranging from 13% to
88%, whereas a single pediatric study reported a low magnesium
intake relative to the RDA (EFSA RDA: 80 mg/day for age 7–11
months, 170 mg/day for age 1–3 years, 230 mg/day for age 3–10
years, 300 mg/day for boys and 250 mg/day for girls for age 10–18
years) (7).
Calcium
Many patients with IBD have a low dairy calcium intake
(73,111). In adults, the effect of calcium (and vitamin D)
supplementation on bone mineral density (BMD) is controversial
(112). In children with IBD, an open-label, prospective study
about the effect of calcium and vitamin D supplementation on
BMD suggested that supplementation of calcium and vitamin D
does not improve BMD (113). Nevertheless, it is well-known that
patients with IBD have an increased risk of reduced BMD (114–
117). It has been reported that children with IBD have low BMD,
with almost 50% having BMD z scores <1 SD and around 25%
having BMD z scores <2 SD, regardless of sex (114–116,118).
Numerous factors have been implicated in suboptimal bone
mineralization, including chronic systemic inflammation, malnu-
trition, corticosteroid treatment, delayed puberty, growth retar-
dation, low BMI, and a sedentary lifestyle (119,120). The
diagnosis of osteoporosis in adults is based on assessment of
BMD by DXA. In young adults, osteoporosis is defined as a
BMD value at least 2.5 standard deviations lower than the mean
BMD for young healthy adults (t score  2.5) (121). In
children, the relationship between BMD and fracture risk is
not well established and reference to the z score has been
recommended. A z score <2 should be reported as ‘‘below
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expected range for age’’ and the need for treatment interpreted in
the context of fracture risk factors (122). In the absence of further
evidences, screening recommendations for DXA in children with
IBD should not differ from the general population and should be
limited to those patients at higher risk, such as long-term use of
corticosteroids.
Fat-soluble Vitamins
Do children with IBD have a risk for vitamin D deficiency?
What is the best option to treat vitamin D deficiency?
Can vitamin D and/or calcium supplementation improve BMD?
What is the risk for deficiencies of fat-soluble vitamins in
children with IBD and should these be monitored?
Statements:
 We recommend monitoring vitamin D levels in all
children with IBD (EL 2).
 Vitamin D supplementation is recommended in
children with IBD when vitamin D deficiency is
present (ie, 25(OH) D concentrations below
50 nmol/L or 20 ng/mL) (EL 3).
 Due to insufficient data, we do not recommend
routine measurement or supplementation of
vitamins A, E, and K in the absence of chronic
liver disease (EL 2).
Practice points:
 A serum 25(OH) D concentration above 50 nmol/L
or 20 ng/mL indicates sufficiency, whereas serum
concentration below 25 nmol/L or 10 ng/mL sug-
gests severe vitamin D deficiency.
 A standard weight-based dose for replenishment
of vitamin D in children with IBD has not been yet
established. Evidence implies that high doses (ie,
2000 IU daily or 50,000 IU weekly) and long-
term treatment may, however, be necessary to
maintain sufficiency.
Vitamin D
The main function of vitamin D is the regulation of calcium
and phosphate. It is essential for bone health but also has an
important role in immune regulation. In infants and children, a
serum 25(OH) vitamin D concentration >50 nmol/L or 20 ng/mL
indicates sufficiency (123,124). There is, however, insufficient
evidence demonstrating that vitamin D supplementation provide
measurable health benefits other than providing adequate blood
levels (125).
Several studies in adult IBD patients including a meta-
analysis reported that patients with IBD had lower serum
25(OH) D concentrations compared with healthy controls with
an inverse correlation to disease severity (126–129). A retrospec-
tive case-controlled study observed no difference in 25(OH) D
levels between children with IBD and healthy controls (130). In
contrast, 2 pediatric studies reported that serum level of 25(OH)D
were significantly lower in children with IBD compared to a
controls with no correlation to either BMD (131) or to disease
activity (132). Predisposing factors included dark skin, winter
season, and more severe disease. Pediatric studies observed a
19% to 35% rate of vitamin deficiency in children with IBD,
associated with greater corticosteroid exposure (133). The question
remains as to whether vitamin D deficiency is truly a cause or effect
of IBD activity in humans.
Two pediatric IBD randomized controlled trials (RCTs) have
not found significant differences in the effect of different oral doses of
vitamin D ranging from 400 IU to 2000 IU daily (134,135) whereas 1
RCT did show benefit for higher range doses (either 2000 IU daily or
50,000 IU weekly)(136). A recent trial demonstrated a significant
though short-term effect of either 10,000 IU or 5000 IU per 10 kg
body weight per week for 6 weeks (137). Regular supplementation of
2000 IU daily or 50,000 IU weekly was, however, successful in
replacing deficiency in the long term (71). A single age-based high-
dose oral cholecalciferol (Stoss) sustained sufficient vitamin D levels
for at least 6 months (138).
Supplementation with daily calcium and vitamin D was
associated with BMD increment in adult IBD patients (139). An
open-label, prospective study in children with IBD, however,
suggested that supplementation of calcium and vitamin D does
not affect BMD (114).
Vitamin A
Vitamin A (measured as retinol or b-carotene levels) was
shown to be variably low in adult IBD patients (7,140–142). The
DRI for daily vitamin A consumption was not met in 36% to 90% of
IBD patients. Vitamin A deficiency was found in 14% of 97
children with IBD and was associated with increased disease
activity (143).
Vitamin E
Of the few adult studies assessing vitamin E status in IBD
patients (142,144,145) only 1 found a significantly lower serum
level in CD patients. Two small pediatric cohorts did not demon-
strate significant difference in vitamin E levels between IBD
patients and controls (70,112). A single pediatric study demon-
strated overall deficiency of 6%, which increased to 40% of those
with moderately to severely disease (143).
Vitamin K
Vitamin K deficiency has been scarcely reported in adult
patients with IBD (more commonly in CD) with a weak correlation
to active disease (146–148). In adult CD patients, low levels of free
and bone-vitamin K were found to be associated with low BMD
(147). In a recent pediatric study, the prevalence of vitamin K
deficiency was 54.0% in CD and 43.7% in UC and correlated with
disease activity (149).
Water-soluble Vitamins
What is the risk for deficiencies of water-soluble vitamins in
children with IBD and should these be monitored?
What is the recommended supplementation of folic acid in
children with IBD receiving methotrexate (MTX)?
When should vitamin B12 level be monitored in children with
IBD and how vitamin B12 should be supplemented in the case of
deficiency?
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Statements:
 We recommend monitoring folic acid annually
(EL 2).
 We do not recommend routine measurement or
supplementation of vitamin B1, B2, B3, B6, B7 and
vitamin C in children with IBD (EL 2).
 We recommend folic acid supplementation (either
1 mg daily or 5 mg weekly) in children with IBD
receiving MTX therapy (EL 2).
 We recommend that either serum cobalamin levels
or methylmalonic acid level in blood or urine should
be measured in children with active ileal CD, chil-
dren with ileal resection of>20 cm and UC children
ileal pouch surgery at least annually (EL 4).
 We recommend that vitamin B12 supplementation
is given intramuscularly for pediatric IBD patients
with evidence of vitamin B12 deficiency (EL 2).
Practice points:
 Clinically significant deficiency of folate is uncom-
mon in children with IBD. Nevertheless, consid-
ered the increased risk when compared to the
healthy children, we suggest to measure either
serum folate level or folate level in red blood cells
(RBCs) at least annually, or if macrocytosis is pres-
ent in the absence of thiopurine use.
 Folate supplementation of 1 mg/day is usually
sufficient to replenish deficient folate stores within
2 to 3 weeks; however, the folic acid requirement
of children with CD has not been determined.
 CD patients with terminal ileal resection of>20 cm
have the greatest risk for vitamin B12 deficiency.
Patients with distal ileal resection of >60 cm will
require lifelong B12 supplementation.
 Patients with extensive distal ileal resection or with
clinical deficiency of vitamin B12 should receive
1000mg of injected B12 every other day for 1 week
and then weekly until clinically improved, followed
by periodic injections according to methylmalonic
levels.
Vitamin C
Hypovitaminosis C is not uncommon in adult IBD patients
and appears to be equally common in patients with UC or CD
regardless of disease activity (112,141,150).
Vitamin B1
Thiamine deficiency was shown to be more common in CD
patients compared with controls even when disease is in remission
(7,151). High-dose oral thiamine in IBD patients was shown to
improve fatigue symptoms in an open-label pilot study (141). This
observation calls for well conducted studies and the authors sug-
gestion that, high dose may enhance cellular transport thus affecting
fatigue, needs to be examined.
Vitamin B2
Riboflavin deficiency does not appear to be common in IBD,
with only few studies reporting a relative low intake of riboflavin in
adults (71,150,152) and in children (7,153).
Vitamin B3
A single study found that 77% of adult CD patients have low
plasma vitamin B3 during remission (112).
Vitamin B6
Two studies reported 10% to 13% rates of vitamin B6
deficiency in adult IBD patients (145,154). Low intake of B6
was reported in children with IBD (155).
Vitamin B7
Two studies yielded contradictory results regarding of biotin
status in IBD patients (145,150).
Folate (B9)
Folate levels can be measured in serum or more accurately
in RBC and also by measuring serum homocysteine levels.
Several adult studies showed that folate deficiency ranges from
20% to 30% in CD patients and 4% to 10% in UC patients,
particularly in patients with active ileitis or history of small
bowel resection (155–157). A study using RBC folate levels,
however, yielded much lower rates of deficiency (0%–7%) (73).
Studies in children are more controversial with results ranging
from low (158) through normal (70,71) and even high serum
folate levels (159,160).
Both sulfasalazine and MTX can cause folate deficiency, as
both are inhibitors of dihydrofolate reductase and cellular uptake of
folate (125). A recent systematic review showed that folic acid
supplementation in MTX-treated patients with rheumatoid arthritis
reduces the incidence of abnormal liver function tests, gastrointes-
tinal (GI) adverse effects, and rates of withdrawal from treatment
(161). The optimal dosage of supplementation has not been estab-
lished though either a daily dose of 1 mg or a weekly dose of 5 mg
seem to be sufficient (162). ECCO guidelines recommend measur-
ing folate level at least annually, or if macrocytosis is present in the
absence of thiopurine use (83). Folate supplementation of 1 mg/day
is usually sufficient to replenish deficient folate stores within 2 to
3 weeks (163).
Vitamin B12
Vitamin B12 status is measured by either serum B12
levels or more accurately by methylmalonic acid and homocys-
teine levels (164). The causes of vitamin B12 deficiency in
patients with IBD include ileal disease or resection, fistulas,
small bowel bacterial overgrowth and reduced intake (165,166).
A systematic review, including 3732 patients, concluded that
B12 deficiency in patients with UC or with CD with no ileal
resection (or resection of <20 cm) is no more common than in
the general population (165). Using methylmalonic acid levels
B12 deficiency, however, increased to 32% and was associated
with active terminal ileitis (167). Vitamin B12 deficiency was
also demonstrated in UC patients with ileoanal pouch (168).
Pediatric data are scarce with 2 small cohorts yielding contra-
dictive results (70,169). Previous studies demonstrated that
patients with terminal ileal resections of >60 cm will need
lifelong B12 replacement (169), whereas up to 48% of patients
with resection of 20 to 40 cm are at risk of eventually develop-
ing B12 deficiency (170).
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ECCO guidelines recommend assessing cobalamin level
at least annually or when macrocytosis is present, in the
absence of thiopurine use (83). Vitamin B12 status should be
assessed in patients with active ileal CD or history of ileal
resection (>20 cm), although the recommended intervals for
screening have not been established (165). Patients with clini-
cal deficiency should be treated with scheduled intra-muscular
injections (171).
NUTRITION AS A PRIMARY THERAPY IN
INFLAMMATORY BOWEL DISEASE
Parenteral Nutrition
How efficient is parenteral nutrition (PN) induction of remis-
sion in children with IBD?
Statement:
 PN should not be used as means to induce remis-
sion in pediatric CD (EL 4).
Practice points:
 PN should only be used when oral nutrition sup-
port or enteral support is insufficient to meet the
patients’ requirements or when enteral feeding is
contraindicated.
 In selected cases, when enteral nutrition (EN)
cannot be used, PN may have a role as a support
therapy within the preoperative period in children
undergoing elective surgery.
 PN is more expensive and raises safety concerns in
comparison to EEN.
Indications for PN in pediatric patients with IBD
Chronic intestinal failure necessitating the need for home PN
is uncommon in CD and is observed mainly in adults due to
resections of a significant portion of the small intestine (172). In
the largest cohort of home PN published recently, of 251 pediatric
patients on home PN, 9 had CD and 4 had UC (173). If intestinal
failure occurs and when EN is contraindicated (hemodynamic
instability, intestinal ischemia, intestinal obstruction, ileus, severe
intestinal hemorrhage, and high-output fistulae), the individual
nutrition goals should, however, be met by the provision of PN.
Preferably, this should be limited to a short period (few weeks);
however, in cases of intestinal failure this may need to be done
indefinitely.
Should PN be used to induce remission in children with IBD?
In 1 study, EN was as good as PN for induction of remission
and the probability to remain in remission after 1 year (174). In
another study, elemental diet and PN were equally as effective in
remission induction (175).
Overall, PN only has a role in children with or at risk of
malnutrition and in children in need of nutrition support where the
use of EN is contraindicated or is insufficient to maintain nutritional
status and growth. Although it was never adequately studied in
children, clinical wisdom as well as costs and safety concerns,
however, should limit the use of PN to its classical roles as
stated above.
EXCLUSIVE ENTERAL NUTRITION
What is the efficacy of EEN for the induction of remission of
pediatric CD?
Statements:
 EEN has the same efficacy as oral steroids in the
induction of remission of children with active lumi-
nal CD (EL 1).
 EEN may be re-used during the course of disease in
case of relapse (EL 2).
Although no placebo-controlled RCT of EEN have been
conducted, several RCTs summarized in 3 different meta-analyses,
established the efficacy of EEN for the induction of remission in
children with CD (176–178). As stated in the most recent guidelines
on the therapeutic management of pediatric CD (45), the overall
combined remission rate for EEN is 73% (relative risk 0.95, 95%
confidence interval 0.67–1.34 (177) and relative risk 0.97, 95%
confidence interval 0.7–1.4 (178). After the publication of the last
meta-analysis, 1 RCT and some other prospective studies were
published replicating the previous results (179–182). The overall
conclusion is that EEN has the same efficacy in the induction of
remission as corticosteroids. Recently, the efficacy of EEN has been
confirmed in comparison to biological therapy. Lee et al (183)
enrolled 90 consecutive children with an active CD in a prospective
study. Patients received EEN, infliximab or partial enteral nutrition
(PEN) as therapy for induction of remission. Clinical response was
achieved in 88% of children treated with EEN, 84% of those receiving
biological therapy and 64% in children undergoing PEN (183).
In conclusion, considering all the benefits of EEN and taking
into account the adverse effects of steroids, EEN should be consid-
ered as the first-line therapy to induce remission in pediatric luminal
CD (45).
Few retrospective studies evaluated the efficacy of a second
course of EEN as induction therapy during the course of the disease.
Remission rates ranged from 58.3% to 80% (184–187). In the most
recent retrospective study including 52 children, Frivolt et al (187)
reported a 92% of remission rate after the first cycle of EEN and
77% after a second cycle of EEN, although a second cycle was used
in only 26 children. These data confirm that if the compliance of the
patients is maintained, EEN may be successfully reused during the
subsequent course of the disease for future relapses.
Type of Formula and Delivery Mode
Statement:
 The use of standard polymeric formula, with a
moderate fat content, is recommended unless
other conditions are present (eg, cow’s milk pro-
tein allergy) (EL 1).
Practice points:
 There is no evidence that the dietary source of
proteins affects the efficacy of EEN.
 Initially the formula should be administered orally.
A nasogastric tube may be used when there is
failure to achieve adequate oral intake.
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The source of proteins seems not to affect the efficacy of
EEN. Indeed, numerous studies have compared the efficacy of
different types (elemental, semi-elemental, oligomeric, or poly-
meric diets) of enteral formulas in the management of active CD
with no significant results (188–190). This was further confirmed
by a Cochrane meta-analysis of 10 trials showing no statistically
significant difference between patients treated with elemental
and non-elemental diet (191). Therefore, unless cow’s milk
protein allergy co-exists, polymeric formula should be preferred
considering the better palatability and the lower costs (192).
Given the pro-inflammatory properties of some lipids, fats’
composition of formulas has been postulated as one of the possible
mechanism to explain EEN efficacy. Although, no studies have
been published in pediatrics, 2 adults’ trials demonstrated no
differences when increasing medium-chain triglycerides (193) or
monounsaturated fatty acids content in the formulas (194). Simi-
larly, a subanalysis of a Cochrane demonstrated no differences in
induction of remission of CD between low-fat and high-fat
formulas (48). Finally, the addition of metabolites with anti-
inflammatory properties such as glutamine (68) or omega-3
(116,117) has not given positive results and should not be recom-
mended.
To date, few formulas with the adequate caloric intake are
available and successfully used for delivering EEN in children. No
comparison study in terms of effectiveness has, however, been
performed so far.
No differences in term of efficacy have been observed between
oral EEN and continuous administration through a nasogastric tube
(181). Considering that the use of a nasogastric tube may decrease the
improvement of QoL achieved with EEN (195), oral feeds should be
preferred. A nasogastric tube should be positioned if adequate caloric
intake could not be achieved orally (45).
Duration and Reintroduction of Foods
Statement:
 EEN is recommended for a period of at least
8 weeks (EL 1).
Practice point:
 There is still insufficient evidence to recommend a
standard food reintroduction scheme. In the
absence of evidence we suggest a gradual reintro-
duction of the foods, with a concomitant reduc-
tion of the formula over a 2- to 3-week period.
There is no evidence regarding the precise duration of
EEN. Duration of EEN in clinical studies varied from 2 to 12
weeks, with majority using 6 to 8 weeks (196). Symptoms
usually improve after a few days on EEN and mucosal healing
was demonstrated after 8 weeks (197). In accordance with the
last CD guidelines we suggest that EEN induction therapy should
last at least 6 weeks (45).
There is no evidence to guide reintroduction of normal food
after the EEN. Recently, Faiman et al (198) conducted a retro-
spective study comparing a standard food reintroduction over 5
weeks versus a rapid reintroduction over 3 days. No significant
differences were observed in terms of relapse rate and maintenance
of remission over 1 year. The authors concluded that due the better
tolerability, a rapid reintroduction should be preferred (198). This
study, however, suffers several limiting factors; it was retrospec-
tive and had high drop-out (20 of 31 children with slow introduc-
tion and 19 of 33 were included in the analysis). In the absence of
more solid evidences, a gradual food reintroduction with concom-
itant decrease of formula volume over a 2- to 3-week period, as
suggested in CD guidelines (45), should still be the preferred
approach.
Location and Behavior of Disease
Statement:
 EEN should be recommended in all cases of active
luminal disease irrespective of the GI tract location
(EL 2).
Practice point:
 There is insufficient evidence to recommend EEN
for isolated oral or perianal disease and for extra-
intestinal manifestations.
Opposing data exist regarding the efficacy of EEN and CD
disease location. Previous studies (197,199) suggested a better effi-
cacy of EEN in patients with ileal involvement compared to isolated
colonic disease. More recent data, however, demonstrated no signifi-
cant differences between isolated colonic disease and small bowel
CD (181,184). Particularly, in the retrospective study from Rubio et al
(181), which included 106 CD patients, no significant difference was
observed regarding location of disease. Conversely, another retro-
spective analysis including 114 children reported that individuals
with isolated terminal ileal disease (n¼ 4) had lower remission rates
than other locations (P¼ 0.02) (180). In the absence of better
scientific evidence, these data support the conclusions of the
Cochrane meta-analysis, which suggested the use of EEN in all
pediatric CD patients with luminal disease, irrespective of the disease
location (176).
To date there are no data to support the use of EEN in patients
with isolated extraintestinal manifestations or oral disease. Efficacy
of EEN for active perianal disease was reported only in a small case
series (200).
Adverse Effects
Practice points:
 Clinicians should be aware of the risk of refeeding
syndrome in severely malnourished children.
 Other possible adverse effects include nausea/vomit-
ing, diarrhea, abdominal discomfort, bloating.
EEN is associated with minimal and temporary adverse
effects. Most common reported are nausea, diarrhea, constipa-
tion, abdominal pain, and bloating (201). Borrelli et al (202)
reported that 4 of 17 patients (23.5%) had mild GI adverse
effects. The only severe reported adverse event was refeeding
syndrome. Refeeding syndrome is defined as a potentially fatal
metabolic complication causing shifts in fluids and electrolytes
(especially hypophosphatemia) that may occur in severely
Miele et al JPGN  Volume 66, Number 4, April 2018
696 www.jpgn.org
 Copyright © ESPGHAN and NASPGHAN. All rights reserved.
malnourished patients after the start of refeeding (203).
Refeeding syndrome has been described in 3 case reports in
malnourished CD children (204,205). Therefore, the awareness
of a clinician for this life-threatening complication is
essential, because the risk of refeeding syndrome can be
dramatically decreased by a slow increase of EEN (volume
and concentration) over several days, starting with reduced
caloric intake (last known intake or 50%–75% of the REE
and advancing only when there are no significant electrolyte
abnormalities.
What is the efficacy of EEN for the maintenance of remission of
pediatric CD?
Statement:
 There is no evidence for using EEN as a mainte-
nance therapy (EL 4).
Practice points:
 Due to the highly demanding adherence, EEN
should not be considered as an option for long-
term maintenance therapy.
No study has evaluated the role of EEN for the maintenance
of remission in children with CD. Due to the low compliance of
patients after the induction cycle, we do not recommend EEN for
the maintenance of remission in children with CD.
What is the efficacy of EEN for the induction and maintenance
of remission of pediatric UC?
Statement:
 EEN is not efficacious in the induction and main-
tenance of remission of pediatric UC (EL 4).
What is the efficacy of EEN onmucosal healing of pediatric CD?
Statements:
 EEN promotes mucosal healing (EL 2).
 EEN also promotes transmural healing in a propor-
tion of patients.
Effect of EEN on mucosal healing was investigated by 7
studies (181,195,197,202,206–208) where endoscopy was per-
formed 8 or 10 weeks after initiation of EEN. All studies found
improvement in mucosal inflammation and complete mucosal
healing was found in 19% to 87% of patients. Two studies, 1
open-label RCT (202) and other retrospective study (208) com-
pared mucosal healing between children treated with corticoste-
roids and with EEN. Both studies found significantly higher rate of
mucosal improvement in EEN group (42% vs 87% and 0 vs 19%).
Furthermore, there is evidence that early endoscopic response is
associated with reduced relapses, hospitalization and need for anti-
TNF treatment at 1 year of follow-up (207). In 3 of 14 (21 %)
children EEN was even able to induce complete transmural remis-
sion of ileal CD (207).
What are the long-term outcomes of EEN?
Statements:
 EEN improves nutritional status (EL 2) and QoL
(EL 3).
 There is insufficient evidence at present to show
that EEN improves long-term bone health (EL 4).
a) Remission duration
Remission duration after EEN is not well determined. Overall
11 studies (179,185–187,192,197,198,208–211) reported
relapse rate in the longer period (10 months to 7 years).
Relapse rate ranged from 42% to 67% in the first year
(187,192,198,209,211) and 58% to 68% at 24 months
(179,186,211). Median time to first relapse ranged from 6.5
to 12.7 months (185–187). Duration of remission after
induction with EEN versus corticosteroids was assessed by 3
studies and results were contradictory. Thomas et al (210)
found shorter remission duration after EEN, but 2 more recent
studies found longer duration of remission if EENwas used as a
first-line induction therapy (208,209). Furthermore, although it
did not report difference in remission duration after EEN or
corticosteroids, 1 study reported protection against relapses in
EEN group during the 24 months period (211). These results,
however, should be interpreted with caution due to their
retrospective nature and high possibility of other confounding
factors.
b) Growth and bone health
All studies investigating weight change during EEN treatment
reported positive effect of EEN on weight. Three studies
showed an increase in lean body mass (53,212,213). Results on
height increase are conflicting. Some studies reported height
velocity increased immediately after the EEN treatment
(202,207,208,214). Furthermore, there is no agreement on
long-term results; retrospective studies with no comparative
cohort found no significant long-term improvement in height z
score (185–187); studies which compared EEN and corticoste-
roids found conflicting results: 2 studies (210,215) found better
growth rate if EENwas used as a primary induction therapy and
one showed no difference (216).
The influence of EEN on bone health has been investigated by 3
studies (213,216,217). Werkstetter et al (213) prospectively
evaluated data on bone quality using peripheral quantitative
computed tomography and found improved bone metabolism
within 3 months of starting EEN with no further normalization
afterwards (1 year of follow-up). EEN therapy also normalized
markers of bone turnover 8 weeks after EEN introduction
(217). After a follow up of 1 year EEN group had a non-
significant improvement in BMD assessed by DXA (216).
c) Quality of life
Two studies evaluated QoL after the treatment with EEN both
showing improvement in QoL scores after EEN (183,195).
Additionally, patients who received EEN comparing to partial
EN and anti-TNF therapy had similar improvement in QoL
scores (determined by IMPACT score) (183).
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PARTIAL ENTERAL NUTRITION
Definition
PEN is defined as providing subjects with a nutritionally
balanced liquid formula while continuing to eat an unrestricted or
exclusion diet.
What is the efficacy of PEN for the induction of remission of
pediatric CD?
Statement:
 PEN alone should not be used for induction of
remission (EL 2).
Practice points:
 PEN alone is not efficacious to induce remission in
the majority of patients.
 Supplementation with a standard polymeric for-
mula, in addition to conventional induction treat-
ment may be considered.
Johnson et al (218) showed in an RCT the superiority of EEN
over PEN in clinical remission rates defined using the Pediatric
Crohn’s Disease Activity Index (PCDAI) as the primary outcome
measure at 6 weeks (10/24 [42%] vs 4/26 [15%], respectively,
P¼ 0.03). In this study, PEN provided an average of 47% of total
energy requirements (range 39%–58%).
Additionally, a recent prospective study of children initiating
PEN, EEN, or anti-TNF therapy for active CD, confirmed that each
therapy improved symptoms, but EEN and anti-TNF therapies were
significantly superior to PEN providing between 80% and 90% of
estimated calories needed for inducing mucosal healing (183). In a
retrospective cohort of 28 children with CD, supplementation with
polymeric formula, additionally in conventional treatment, was
associated with a decrease in PCDAI, whereas children who were
not on supplementation did not (219). Gupta et al (220) administered
formula overnight to deliver 80% to 90% of overall needs with the
remaining 10% to 20% of their caloric needs came from an unre-
stricted diet of small meals or snacks during the day. This was
effective for the induction of remission in pediatric patients with
CD. More recently, Sigall-Boneh et al (221) proposed a dietary
intervention in mild-to moderate CD, based on 50% PEN and a
structured exclusion diet, which led to remission in 70% of children.
What is the efficacy of PEN for the maintenance of remission of
pediatric CD?
Statement:
 PEN is a treatment option to maintain remission in
selected patients with mild disease and low risk of
relapse (EL 4).
What is the optimal daily amount and recommended duration
of PEN for the maintenance of remission of pediatric CD?
Statement:
 The optimal daily amount and the duration of PEN
that needs to be consumed to be effective are
unknown (EL 4).
Practice points:
 A long- or short-term PEN course, in addition to
unrestricted normal or specific food diet may be
offered inorder toprolong theperiod of remission in
patients who are on no other maintenance treat-
ment for CD.
Long-term enteral nutritional supplementation, in addition to
unrestricted normal or specific food diet, such as low-fat diet, may
prolong the period of remission and reduce relapse rates in patients
with CD. There is limited research evidence relating to maintenance
EN as a treatment for pediatric CD patients, with many of the best
studies being performed in adults (222). Yamamoto et al (222)
performed a systematic review in adult CD, including 10 studies: 1
RCT, 3 prospective nonrandomized trials, and 6 retrospective
studies. The clinical remission rate was significantly higher in
patients receiving PEN in all 7 studies comparing PEN to non-
supplementation. Additionally, in 2 studies, PEN showed reduction
in endoscopic disease activity. There are a smaller number of
pediatric studies. Wilschanski et al (223) showed retrospectively
that providing PEN (nocturnal nasogastric supplements), without
restriction of normal diet, after successful treatment with EEN, was
associated with prolongation of remission and improved linear
growth. Duncan et al (224) demonstrated that a subgroup of patients
can successfully continue PEN supplements postinduction of remis-
sion with EEN as an effective maintenance treatment and had 1 year
remission rates matching thiopurines. PEN therefore seems a useful
strategy in a subgroup of patients especially in those who are not
commencing azathioprine or similar maintenance treatments. In
contrast to the previous studies suggesting the efficacy of PEN,
Knight et al (185) reported that the intake of maintenance enteral
feeding was not associated with significantly decreased relapse rate.
In adult studies investigating the impact of the quantity of
enteral formula on clinical remission, higher amounts of enteral
formula (35%–50%) were associated with higher remission rates
(225,226). In children the proportion of PEN varies between
studies. It is clear that further studies are needed to find appropriate
amount, duration, timing of PEN (185).
PROBIOTICS AND PREBIOTICS IN
INFLAMMATORY BOWEL DISEASE
What is the clinical efficacy and safety of probiotics, when
compared to no treatment, placebo, pharmacological treatment,
or alternative nonpharmacological treatment in the induction
and maintenance of remission of pediatric UC and CD?
Statements:
 There is limited evidence in favor of using VSL#3 or
Lactobacillus reuteri ATCC 55730 as adjuvant to
standard therapy for induction of remission in
mild-to-moderate pediatric UC (EL 2).
 There is evidence in favor of using VSL#3 or Escher-
ichia coli Nissle as an alternative to 5-ASA therapy
in maintenance of remission in mild-to-moderate
pediatric UC especially in mesalazine (5-ASA)p
intolerance (EL 2).
 VSL#3 has shown efficacy for maintaining antibi-
otic-induced remission in pouchitis and for pre-
venting it in adults (adult EL 2; pediatric EL 5).
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 We do not recommend the use of probiotics in the
induction or in the maintenance of remission of
pediatric CD (EL 2).
Practice points:
 Probiotics should be used with caution in patients
with central venous catheter or in immunocom-
promised patients.
 Results from clinical trials are strain-specific and
should not be extrapolated to other bacterial strains.
High-quality studies on the effect of probiotics in pediatric
IBD are limited, with only 3 RCTs 2 in UC (227,228) and 1
in CD (229). Some extrapolations can be made from adult data
(230–241), but these have limited applicability in the pediatric
population.
Ulcerative Colitis
Oliva et al (228) showed an effect on decrease of both
endoscopic (Mayo score) and histological score during 8 weeks
of follow-up in group of pediatric patients treated by rectal enema
containing L reuteri ATCC 55730 in addition to 5-ASA treatment,
but not in placebo arm in mild-to-moderate active distal pediatric
UC. Miele et al (227) has shown VSL#3 to be superior to placebo in
both induction and maintenance of remission (1-year follow-up)
when added to standard treatment in pediatric newly diagnosed UC.
An open-label study of VSL#3 in induction of remission in
children with mild to moderate active UC (242) and another small
study on E coli Nissle showing efficacy comparable to 5-ASA in
maintenance of remission in pediatric UC (not an RCT) (243) were
excluded.
In adults, neither ECCO (231) nor Cochrane review (234)
recommend probiotics for induction of remission of mild-to-mod-
erately active UC, despite some studies showing some effect of
VSL#3 (227,244–247). There are no relevant data on probiotics in
treatment of acute severe colitis (248).
Based on several RCTs and in accordance with systematic
reviews (235,249), ECCO recommend E coli Nissle as an
effective alternative to 5-ASA for maintenance therapy in adult
UC (231).
Current pediatric UC guidelines (250) conclude in accor-
dance with the Cochrane review (236) that there is insufficient
evidence to recommend routine use of probiotics for induction or
maintenance of remission in pediatric ambulatory UC patients.
Some probiotics (VSL#3, E coli Nissle) may, however, be consid-
ered in children with mild UC intolerant to 5-ASA, or as an adjuvant
therapy in those with mild residual activity despite standard ther-
apy. Therapy with VSL#3 has also shown efficacy for maintaining
antibiotic-induced remission and for preventing pouchitis in adults
(237,239,240). Recently, the probiotic mixture VSL#3 has changed
manufacturer and although it contains the same bacteria, its efficacy
under the new manufacturing conditions has not yet been scientifi-
cally tested in IBD clinical trials.
Crohn’s Disease
Only 1 relevant pediatric study was identified showing that
Lactobacillus GG is not superior to placebo in addition to standard
maintenance therapy in pediatric CD (229). Moreover, a meta-
analysis has even concluded that Lactobacillus GG may increase
incidence of relapse in children (251). Also, Saccharomyces bou-
lardii has not shown any efficacy in preventing of relapse in CD
adult patients in remission of disease (252). Current pediatric CD
guidelines (45) as well as adult ECCO guidelines (232) and
Cochrane review (238) are in accordance that there is no significant
benefit of probiotics for reducing the risk of relapse compared to
standard maintenance therapy.
What is the clinical efficacy and safety of prebiotics, when
compared to no treatment, placebo, pharmacological treat-
ment, or alternative nonpharmacological treatment in the
induction and maintenance of remission of UC and CD?
Statement:
 There is no evidence to the use of prebiotics and/or
synbiotics in the induction and in the maintenance
of remission of pediatric UC (adult: EL 2; pediatric:
EL 5) and CD (adult: EL 2; pediatric: EL 5).
There are few data on the effect of prebiotics and synbiotics
in pediatric IBD, with no published clinical trial. The majority of
data in adults are limited by the small sample size, short duration
and high dropout rate (253–260). A systematic review of RCT
published in 2015, based on major limitations of the studies,
including different agents used, sample size, and methodological
issues, concluded that there is inconclusive evidence of a beneficial
role of prebiotics and synbiotics in IBD (261).
What is the clinical efficacy and safety of dietary fibers, when
compared to no treatment, placebo, pharmacological treat-
ment, or alternative nonpharmacological treatment in the
induction and maintenance of remission of UC and CD?
Statements:
 Based on adult studies, fiber supplement interven-
tion may be effective in the management of UC
and pouchitis (adult: EL 2; pediatric: EL 5).
 There is no evidence to support high-fiber or low-
fiber diet in CD (adult: EL 2; pediatric: EL 5).
Practice points:
 A possible effect of fiber supplementation associ-
ated with standard therapy has been reported in
maintenance of remission (psyllium fiber), in active
UC (germinated barley fiber), and in maintenance
of remission in pouchitis (inulin-enriched oral sup-
plement).
 Fiber restriction should not be recommended in
patients with IBD without evidence of stricturing
phenotype.
The scientific rationale of using dietary fiber in IBD relates to
the production of metabolites (ie, SCFAs, particularly butyrate) and a
beneficial influence on GI functions (262). Although no specific
pediatric study has been performed, several trials in adults have
evaluated the effectiveness and mechanisms of action of fiber in IBD.
Based on the published RCT in adults and on 3 systematic reviews,
there is limited evidence for the effectiveness of fiber supplementa-
tion in active UC and in maintenance of remission in UC and
pouchitis (253,254,263–274). Data in active UC are conflicting,
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with few studies reporting a possible effectiveness of fiber supple-
mentation and others no effect on disease outcomes (8,10,14)
Dietary intervention studies did not show any significant
benefit of high versus low-fiber diets in CD (263,264,269–271).
Based on the current evidences, no dietary fiber restriction should
be recommended to patients with IBD without evidence of strictur-
ing phenotype, although monitoring of potential fiber intolerance
intake should be performed (262).
SPECIFIC DIETARY RESTRICTIONS FOR
PEDIATRIC INFLAMMATORY BOWEL DISEASE
Statement:
 Elimination or restrictive diet in children/adoles-
cents with IBD should not be recommended unless
potential benefits outweigh potential risks of the
diet (EL 4).
Several diets restricting 1 or more foods from the diet have
been advocated for pediatric and adult patients with IBD to improve
symptoms and/or inflammation (273,275–278). In general, restric-
tive diets may influence nutritional status, psychological and QoL.
Nutritional restriction may result in unbalanced food intake with
deficiency of certain macro- and micronutrients, which may have
negative short- and long-term effect, particularly on the growing
and developing child. Although adults can decide on a specific diet
for themselves children depend on the decision and support by their
caregivers. Diets should only be considered if they have proven
benefit in reducing inflammation, symptoms or both. A list of
reported diets is provided in Table 2.
Specific Carbohydrate Diet
Statement:
 A specific carbohydrate diet (SCD) for induction or
maintenance of remission in pediatric IBD patients
should not be recommended (EL 4).
Practice points:
 SCD is an unbalanced diet due restriction of most
carbohydrates leading to high-protein and high-fat
intake, which has been associated with risk of CD
and UC.
 More evidence on the benefit of SCD from RCTs is
needed before such a dietary restriction can be
recommended to pediatric IBD patients.
The SCD restricts all carbohydrates (starch, polysaccharides,
and disaccharides) except monosaccharides (glucose, fructose, and
galactose). The hypothesis behind is that di- and polysaccharides
are poorly absorbed resulting in overgrowth of bacteria and yeast
with increased mucus production, small bowel injury and malab-
sorption. Two retrospective chart reviews of 7 and 26 children with
IBD on a SCD showed improvement of symptoms and anthropom-
etry (279,280). Nine children with CD were prospectively enrolled
in a trial of SCD while continuing their normal medication.
Laboratory values, PCDAI, and videoendoscopy scores improved;
however, there was no control group and total energy given was
higher compared to the normal diet before starting SCD (281).
Before there is more evidence in favor of an SCD, it cannot be
recommended in children with IBD.
Lactose-free Diet
Statements:
 Symptoms of lactose malabsorption (abdominal
pain, bloating, and diarrhea) overlap with symp-
toms of active IBD (EL 4).
 A diet with reduced lactose intake with monitoring
of symptom improvement may be initiated in
children/adolescents with IBD and symptoms sug-
gestive of lactose malabsorption (EL 3).
Practice point:
 IBD patients should be counseled not to avoid dairy
product, but to reduce high-lactose containing
products and/or to use lactase treated products
TABLE 2. Exclusion diets and related risks in inflammatory bowel disease
Exclusion diets Not allowed foods Risk

Ovo-lacto-vegetarian Meat, fish None
Lactose free (reduced) Animal milk/products high in lactose None, if dairy products low in lactose are not avoided
Vegan All foods from animals Low vitamin A, B12, D, Zinc, low protein intake
Paleolithic diet Potatoes, legumes, cereal grain, domesticated meat, all dairy products,
juices, soft drinks, refined sugar
Increased fats intake; hypocalcemia
Spec. carbohydrate diet Mono-, disaccharides, potatoes, Yams, legumes, canned products,
cereal grains, milks, sweets, margarine, beer
Reduced caloric intake, B and D Hypovitaminosis,
hypocalcemia and hyposideremia
Low FODMAP diet Mono-, di- oligosaccharides, fiber, wheat, rye, many fruits and
vegetables, milk
If long-term, reduction of calcium, folate, thiamin,
vitamin B6
CD exclusion diet
(50% polymeric formula)
Dairy products except the allowed formula, margarine, gluten,
processed and smoked meat and fish, canned products, yeast, soy,
potato or corn flours, soft drinks, fruit juices, alcoholic beverages,
coffee, chocolates, cakes, cookies, gums
None
IgG4-based exclusion Individual, mostly dairy, egg, pork, beef Depending on the excluded foods

Possible nutritional risks in children undergoing diets without nutritional advise.CD ¼ Crohn disease
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or enzyme replacement if lactase deficiency is sus-
pected or intolerance is observed by the patient. If
dietary calcium intake is low, calcium supplemen-
tation should be considered (282).
Hypersensitivity to lactose (lactose intolerance) results from
primary or secondary deficient hydrolysis of lactose in the small
intestine by the brush border enzyme lactase phlorizin hydrolase.
The population proportion of people who are homozygous for the
primary or adult onset of lactase deficiency varies from<10% in white
Northern Europeans to >80 to 90% in regions of Asia and Africa.
Several studies in different populations showed that the primary genetic
form of lactose intolerance occurs in the similar frequencies as in the
respective control population with the same ethnic background (healthy
controls and non-IBD relatives). Secondary lactose intolerance with
lactase deficiency is due to multiple causes resulting in damage of the
microvilli of the intestinal mucosa (eg, inflammation, ulceration,
bacterial overgrowth) or reduction of the intestinal surface (resection).
A few recent studies in children (283,284) have shown that IBD
patients, particularly with small bowel CD, are more frequently lactose
intolerant compared to healthy controls, when assessed by breath
testing, symptoms and measurement of brush border enzyme activity.
Risk of vitamin D deficiency and low Ca intake with negative impact
on bone health has to be taken into account.
Diet Low in Fermentable Oligo-, Di- and
Monosaccharides and Polyol (FODMAPs)
Statement:
 A low FODMAPs diet should not be recommended
for induction to remission in children/adolescent
with IBD (EL 5).
Practice points:
 A strict low FODMAP diet is highly restrictive.
 It may improve IBS symptoms for patients without
evidence of inflammation. It may, however,
decrease diversity and induce dysbiosis.
 FODMAP diet may be responsible for nutrient
deficiencies (Ca, Folate, Thiamin, vitamin B6)
and cannot be maintained for a long period. Die-
tary counseling is strongly advised.
Mono, di-, and polysaccharides and polyols are poorly
absorbed resulting in increased intestinal permeability and
increased functional symptoms (abdominal pain, diarrhea, and
bloating) in patients with IBD (285). A few open nonblinded pilot
studies improved functional GI symptoms in adult IBD patients
(286,287). No pediatric data are available. The diet is low in fiber
serving as prebiotics, with potential negative effects on the micro-
biome and metabolome (288) and a risk of nutrient deficiencies.
Crohn’s Disease Exclusion Diet
Statement:
 A Crohn’s Disease Exclusion Diet (CDED) cannot
be recommended as induction therapy due to
insufficient evidence (EL 4).
Practice point:
 More evidence on the benefit and safety of CDED
from RCTs is needed before such a dietary treat-
ment can be recommended to pediatric
IBD patients.
The diet is based on exclusion of multiple dietary components
(289) and was evaluated for induction of remission in 34 children and
13 adults with mild-to-moderate CD. The investigators used the diet
in conjunction with 50% of caloric intake from 1 of 2 polymeric
formulas. Remission by week 6 was achieved in 70% of patient, with
significant drop in C-reactive protein (CRP) and erythrocyte sedi-
mentation rate at both week 6 and week 12, with normalization of
CRP in 70% of those entering remission (221). Fifteen patients in
remission at week 6, continued dietary restriction and performed a
follow-up evaluation for mucosal healing, 11 of 15 achieved com-
plete mucosal healing. This diet is currently being evaluated in a
multinational multicenter randomized controlled trial.
Other Restrictive Diets
Several other diets have been suggested for treatment of active
CD or UC including the paleolithic diet, a vegan diet, a gluten-free
diet, a diet based on IgG4 testing against foods with excluding foods
with high titers (277). In the latter diet the most common foods
excluded were milk, beef, pork, and egg. The authors reported an
improvement in the symptom score compared to a control group on a
sham elimination diet; however, there was no significant improve-
ment in fecal calprotectin or CRP (290). None of these diets should be
recommended to children and adolescents with IBD at present.
DIETARY COMPOUNDS AND THE RISK OF
INFLAMMATORY BOWEL DISEASE
Definition
Dietary compounds with proven effect on the intestinal
barrier function directly or indirectly via the modification of the
intestinal microbiota potentially implicated in triggering inflamma-
tory or immune-mediated responses leading to IBD.
Practice points:
 Avoidance of ‘‘westernized’’ food (high-fat, high-
protein, high-sugar, low in fruit and vegetables)
identified in epidemiological studies as risk factor
for the development of IBD may be considered.
 Avoidance of high-fat diet (including saturated
milk fats) in patients with IBD may be considered.
 Avoidance of food or beverages containing large
amounts of emulsifiers (ie, sauces, fast foods, mar-
garines, ice-creams) may be considered.
The complex interaction of diet with the host’s immune
system (directly or indirectly via intestinal microbiota) is a key part
in the development of chronic inflammation, the hallmark of IBD.
When considering IBD and diet, there are 2 different aspects: to
identify pre-illness dietary patterns/habits that confer a risk to
develop IBD in susceptible individuals and to identify alimentary
factors that impact on the inflammatory state of patients. Epidemi-
ological or cohort data indicating specific dietary elements as risk
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factors for developing IBD are, however, often used as indirect
evidence to recommend specific nutritional interventions to
treat IBD.
Several epidemiological studies discuss a positive correlation
between western life style (western diet with high amounts of
unsaturated fatty acids, of proteins, a high sugar loads and low
vegetables and fruits intake) and the risk of developing IBD
(291,292). A pediatric study confirmed recently a profound imbal-
ance in fat, vegetables, and fruits consumption and the development
of CD favoring this hypothesis (293). This is in line with adult data
from Japan (294,295) or UK (296) indicating that an increased
consumption of transunsaturated fatty acids increases the risk of
developing UC. A prospective cohort study from France, however,
failed to show any effect of fat or sugar intake, but the same study
identified high protein intake (animal and fish proteins) as positively
correlated to the risk of developing IBD (both CD or UC) (297), in
keeping with the results of Shoda et al (294) who previously identified
a weak positive correlation between high animal and fish protein
intake and the risk to develop IBD. Increased dietary fiber intake has
been associated with a lower risk of developing CD, but not UC (298).
Recently, the results from EPIC study confirmed that high consump-
tion of sugar and soft drinks and low consumption of vegetables are
associated with adult UC risk (299).
Important experimental data support the hypothesis that food
additives, such as emulsifiers or food thickeners (carboxymethyl
cellulose [CMC], carrageenan, polysorbate (P)-60 or P-80, xanthan
gum) can have detrimental effects on intestinal homeostasis. In
vitro and in vivo analyses with CMC or P60 or P80 revealed that
these emulsifiers alter the mucosal epithelial barrier directly or via a
change of the intestinal microbiota biodiversity. They can modify
the mucosa-adherent biofilm and the conditions for adhesion and
translocation of mucosal bacteria. Chassaing et al (300) recently
confirmed in an experimental model that 2 commonly used emul-
sifiers CMC and P80 create low-grade inflammation in wild-type
and in genetically susceptible animals severe colitis, completing
previous experimental work (301,302). It is important to note that
western diet (fast food and sweet beverages) is rich in emulsifiers.
Roberts et al (303) highlighted recently that they observed a clear
correlation between annual emulsifier consumption (in food and
beverages) and the incidence of IBD, in line with previous studies
(292). In the same line, high margarine (rich in emulsifying agents
and hydrogenated fats) was identified by independent studies as
being positively correlated with the development of UC and in some
studies with CD (304,305).
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